Overview

Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder

Status:
No longer available
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to allow patients with specific needs for inhaled insulin to continue with inhaled insulin therapy using Technosphere Insulin after Exubera was withdrawn from the market.
Details
Lead Sponsor:
Mannkind Corporation
Treatments:
Insulin
Insulin, Globin Zinc